Selected article for: "effective vaccine and vaccine trial"
Author: D’Cruz, A.; Parker, H.; Saha, M.
Title: A Bullous Eruption following the Pfizer‐BioNTech COVID‐19 vaccination
  • Cord-id: 09543305
  • Document date: 2021_8_31
    • ID: 09543305
    Snippet: On December 2nd, 2020 the Medicines and Healthcare products Regulatory Agency (MHRA) authorized use of a modRNA - nucleoside modified messenger RNA (mRNA) COVID-19 vaccine; Pfizer- BioNTech. Prior to this, no mRNA vaccines had been authorized for use in humans1 . As of June 2021, 66 million COVID-19 vaccinations have been administered within the UK2 . Currently approved vaccines for use in the UK include Pfizer/BioNTech, Oxford/AstraZeneca, and Moderna variants. An ongoing multinational randomis
    Document: On December 2nd, 2020 the Medicines and Healthcare products Regulatory Agency (MHRA) authorized use of a modRNA - nucleoside modified messenger RNA (mRNA) COVID-19 vaccine; Pfizer- BioNTech. Prior to this, no mRNA vaccines had been authorized for use in humans1 . As of June 2021, 66 million COVID-19 vaccinations have been administered within the UK2 . Currently approved vaccines for use in the UK include Pfizer/BioNTech, Oxford/AstraZeneca, and Moderna variants. An ongoing multinational randomised controlled trial assessing the safety of the Pfizer-BioNTech vaccine reported few localized cutaneous reactions at the injection site, but no significant adverse cutaneous reactions. The data from this study suggested a two-dose regimen of the Pfizer vaccine was safe and effective in 95% of cases3 .

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1